Centessa Pharmaceuticals Acquisition by Eli Lilly - Officer Disposition of Shares and Options

This Form 4 filing reports the disposition of securities by Stephen Kanes, Chief Medical Officer of Centessa Pharmaceuticals plc, following the company's acquisition by Eli Lilly and Company. On June 24, 2026, Eli Lilly acquired all outstanding Ordinary Shares of Centessa through a scheme of arrangement. As a result, Kanes disposed of 120,000 Ordinary Shares (represented by RSUs) and 500,000 share options. The Ordinary Shares were converted to $38.00 per share in cash plus one contingent value right (CVR) per share, with potential additional payments up to $9.00 per share based on milestone achievements. The share options were cancelled and converted to cash equal to the difference between the $38.00 cash consideration and the $16.90 exercise price, plus CVRs. Following the transaction, Kanes holds zero shares and options in the company.